Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Castle Biosciences will present new data on their DecisionDx-Melanoma and DecisionDx-UM tests at the 2024 ASCO Annual Meeting in Chicago from May 31 to June 4, 2024. The DecisionDx-Melanoma test identifies early-stage melanoma patients at higher risk of CNS metastasis, potentially benefiting from more frequent imaging surveillance. The study showed patients with the highest risk (Class 2B) had higher CNS metastasis rates and lower five-year recurrence-free survival. The DecisionDx-UM test, part of a multi-center study, proved more effective than PRAME and DNA mutation status in predicting metastatic outcomes for uveal melanoma.
Castle Biosciences announced a publication demonstrating the efficacy of their DecisionDx-SCC test in identifying high-risk cutaneous squamous cell carcinoma (SCC) patients who benefit from adjuvant radiation therapy (ART). The study, published in the International Journal of Radiation Oncology • Biology • Physics, revealed that patients with Class 2B test results, indicating the highest risk of metastasis, showed a 50% higher metastasis-free survival (MFS) rate when treated with ART compared to those who did not receive ART. Additionally, Class 1 patients, with lower metastatic risk, did not show improved survival with ART, suggesting they can potentially avoid the treatment.
These findings highlight the test's role in guiding clinical decisions regarding ART, thereby optimizing patient care by balancing treatment benefits against side effects.
Castle Biosciences (NASDAQ: CSTL) will present a company overview at the Leerink Partners Healthcare Crossroads Conference on May 29, 2024, at 2:00 p.m. Eastern time. The executive management will provide insights into the company's innovative tests that guide patient care. A live audio webcast of the presentation will be available on the Castle Biosciences website, with a replay accessible post-broadcast.
Castle Biosciences will present three abstracts supporting its TissueCypher® test's effectiveness in predicting esophageal cancer development in Barrett's Esophagus (BE) patients at DDW 2024, May 18-21 in Washington, D.C.
One notable presentation titled 'The Tissue Systems Pathology Test Enables Risk-Aligned Management for Patients with Barrett’s Esophagus' will be delivered by Dr. Lucas Duits. Other abstracts focus on the test's predictive power and clinical applications.
The company has also organized several educational sessions and talks, collaborating with leading GI experts and institutions to enhance patient care.
Castle's activities at DDW 2024 aim to highlight the clinical value of TissueCypher® in managing BE, potentially reducing esophageal cancer incidence through early intervention.
Castle Biosciences, Inc. released new data confirming the effectiveness of DecisionDx-UM in predicting metastasis-free survival in patients with uveal melanoma. The study also validated the PRAME biomarker as a tool to refine risk assessment when combined with the DecisionDx-UM result. The findings were presented at the ARVO 2024 Annual Meeting. Uveal melanoma is a severe eye cancer, and the DecisionDx-UM test is important for determining metastatic risk and guiding treatment plans.
Castle Biosciences, Inc. announced new data supporting the DecisionDx-SCC test in patients with high-risk SCC tumors on the head and neck will be shared at the ACMS Annual Meeting. The test significantly improves prediction accuracy of metastatic events, aiding in risk-appropriate surveillance and treatments.
Castle Biosciences, Inc. (Nasdaq: CSTL) reported a 74% increase in Q1 2024 revenue over Q1 2023, reaching $73 million. Full-year revenue guidance for 2024 was raised to $255-265 million. The company delivered strong financial and operational results, showcasing growth in various test reports. Castle Biosciences continues to develop evidence supporting the clinical utility of its tests, with recent studies demonstrating potential healthcare savings and improved patient outcomes. The company's positive momentum in Q1 sets a solid foundation for continued success throughout the year.
Castle Biosciences, Inc. (Nasdaq: CSTL) kicks off Skin Cancer Awareness Month by supporting various initiatives. The company collaborates with IMPACT Melanoma to honor the City of Friendswood's designation as a Sun Safe Leadership Model City. The Sun Safe Leadership initiative includes programs like free sunscreen dispensers, portable shade tents, prevention education, and protective clothing for outdoor workers. Castle Biosciences partners with various organizations to raise awareness, support fundraising events, and provide education during Skin Cancer Awareness Month.
Summary not available.
Summary not available.